Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk [Yahoo! Finance]
Adagene Inc. - ADS, each representing 1.25 ordinary shares (ADAG)
Company Research
Source: Yahoo! Finance
The company is developing ADG126 as a “masked” anti-CTLA-4 antibody intended to improve the safety of CTLA-4 blockade while enabling higher dosing in combination regimens, particularly with Merck's KEYTRUDA (pembrolizumab). Focus on late-line MSS colorectal cancer without liver metastases Chane-Du said Adagene's initial clinical focus is late-line microsatellite stable colorectal cancer (MSS-CRC) in patients without liver metastases, a setting he described as having low response rates to current standards of care and poor overall survival outcomes. He noted that PD-1 therapies have not shown meaningful activity in MSS-CRC as monotherapy in prior studies and that there is no KEYTRUDA label for this patient population. ? Hinge Health's AI Moat Might Be Its Patient Movement Data Within this subgroup, Adagene is evaluating ADG126 plus full-dose pembrolizumab across multiple dose schedules. Chane-Du said patients without liver metastases represent roughly 30% of MSS-CRC cases, whic
Show less
Read more
Impact Snapshot
Event Time:
ADAG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAG alerts
High impacting Adagene Inc. - ADS, each representing 1.25 ordinary shares news events
Weekly update
A roundup of the hottest topics
ADAG
News
- Adagene to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Adagene to Participate in Two Upcoming Investor ConferencesGlobeNewswire
- BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsightPR Newswire
- BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsightPR Newswire
- ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership ForgingPR Newswire
ADAG
Sec Filings
- 2/17/26 - Form SCHEDULE
- 1/29/26 - Form SCHEDULE
- 1/23/26 - Form 6-K
- ADAG's page on the SEC website